心房颤动患者早期不坚持达比加群与利伐沙班治疗的情况
6个月时达比加群不坚持率36.4%、利伐沙班31.9%,不坚持者卒中/短暂性脑缺血发作/死亡风险显著升高。
要点
- 6个月时达比加群不坚持率36.4%,利伐沙班不坚持率31.9%。
- 不坚持达比加群者卒中/TIA/死亡风险HR 1.76(95%CI 1.60-1.94)。
- 不坚持利伐沙班者卒中/TIA/死亡风险HR 1.89(95%CI 1.64-2.19)。
核心结论
- 临床实践中新型口服抗凝药不坚持率较高,约三分之一患者起始达比加群或利伐沙班后6个月内不坚持。
- 不坚持达比加群或利伐沙班与卒中/短暂性脑缺血发作/死亡等不良临床结局显著相关。
研究设计与样本
- 回顾性队列研究,使用加拿大安大略省1998年1月至2014年3月的行政数据。
- 不坚持定义为达比加群或利伐沙班处方间隔≥14天。
- 采用多因素Cox比例风险模型评估不坚持与卒中、短暂性脑缺血发作和死亡复合结局的关联。
主要发现
- 6个月时,36.4%的患者不坚持达比加群,31.9%的患者不坚持利伐沙班。
- 与坚持者相比,不坚持达比加群者卒中/TIA/死亡风险显著更高(HR 1.76,95%CI 1.60-1.94;p<0.0001)。
- 与坚持者相比,不坚持利伐沙班者卒中/TIA/死亡风险显著更高(HR 1.89,95%CI 1.64-2.19;p<0.0001)。
- 与坚持者相比,不坚持达比加群者卒中/TIA风险显著更高(HR 3.75,95%CI 2.59-5.43;p<0.0001)。
- 与坚持者相比,不坚持利伐沙班者卒中/TIA风险显著更高(HR 6.25,95%CI 3.37-11.58;p<0.0001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dabigatran and rivaroxaban are novel oral anticoagulants (NOACs) approved for stroke prevention in atrial fibrillation (AF). Although NOACs are more convenient than warfarin, their lack of monitoring may predispose patients to non-persistence. Limited information is available on NOAC non-persistence rates and related clinical outcomes in clinical practice. METHODS: We conducted a retrospective cohort study using administrative data from Ontario, Canada, from January 1998 to March 2014 of patients with AF who were dispensed dabigatran or rivaroxaban. Non-persistence was defined as a gap in dabigatran or rivaroxaban prescriptions ≥14 days. A multivariable Cox proportional hazards model was used to estimate the primary composite outcome of stroke, transient ischaemic attack (TIA) and mortality associated with non-persistence. RESULTS: The cohort consisted of 15 857 dabigatran (age 80.7±6.7 year) and 10 119 rivaroxaban users (age 77.0±7.1 year) with women comprising 52% of each medication group. At 6 months, 36.4% of patients were non-persistent to dabigatran, while 31.9% of patients were non-persistent to rivaroxaban. Stroke/TIA/death was significantly higher for those non-persistent to dabigatran (HR 1.76 (95% CI 1.60 to 1.94); p<0.0001) or rivaroxaban (HR 1.89 (95% CI 1.64 to 2.19); p<0.0001) compared with those who were persistent. Risk of stroke/TIA was markedly higher in non-persistent patients to dabigatran (HR 3.75 (95% CI 2.59 to 5.43); p<0.0001) and rivaroxaban (HR 6.25 (95% CI 3.37 to 11.58); p<0.0001) than those persistent. CONCLUSIONS: NOAC non-persistence rates are high in clinical practice, with approximately one in three patients becoming non-persistent to dabigatran or rivaroxaban within 6 months after drug initiation. Non-persistence with either dabigatran or rivaroxaban is significantly associated with worse clinical outcomes of stroke/TIA/death.
引用
- Jackevicius CA, Tsadok MA, Essebag V, et al. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation. Heart. 2017. PMID: 28286333. doi:10.1136/heartjnl-2016-310672
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。